Skip to content

Study identifies children with Autism who benefit from genetic testing.

Autism spectrum disorder (ASD) represents a diverse group of neurodevelopmental conditions. The clinical presentation and outcome vary substantially. The use of genome-wide tests to provide molecular diagnosis for individuals with ASD requires more study and is a big area of interest for many research groups.

Now, a study from researchers at the Hospital for Sick Children, Toronto shows that the use of two newer genetic testing technologies among children with autism spectrum disorder may help identify genetic mutations potentially linked to the disorder. The team states that their study also found that children with certain physical anomalies were more likely to have genetic mutations, findings that may help identify children who could benefit most from genetic testing.  The opensource study is published in the journal JAMA.

Previous studies show that the broad phenotype spectrum of ASD is also reflected in the underlying genetic etiology, which ranges from identifiable monogenic syndromes to large chromosome imbalances. Chromosomal microarray analysis (CMA) is recommended as the first-tier genetic test for individuals with ASD with a yield ranging from 7.0% to 9.0%. Whole-exome sequencing (WES) on research cohorts of individuals with ASD have highlighted sequence-level de novo mutations in the etiology of ASD.  Despite these efforts, the molecular diagnostic yield of WES in a heterogeneous ASD sample is undefined, and CMA data on these same patients may help inform clinical practice.

The current study performed chromosomal microarray analysis (CMA) and whole-exome sequencing (WES) in a group of 258 unrelated children with ASD to determine the molecular diagnostic yield of these tests.  The molecular diagnostic yield is the percentage of subjects with a genetic mutation that may contribute to the features of autism spectrum disorder. All children underwent CMA; a random subset of 95 also underwent WES. All children underwent detailed clinical assessments for the presence of any major congenital abnormalities and minor physical anomalies and were stratified into 3 groups of increasing morphological severity.

Results showed that of the 258 children, 24 (9.3 percent) received a molecular diagnosis from CMA and 8 of 95 (8.4 percent) from WES.  Data findings show that among the children who underwent both CMA and WES testing, the estimated proportion with an identifiable genetic cause was 15.8 percent. This included 2 children who received molecular diagnoses from both tests. The clinical yield for genetic testing was much higher (37.5 percent) in children with ASD who had more complex clinical presentations based on physical examination.

The researchers state that they have demonstrated differences related to morphological stratification of ASD in children based on clinical examination. The findings suggest that medical evaluation of ASD in children may help identify populations more likely to achieve a molecular diagnosis with genetic testing.

The lab note that it appears likely that genetic testing of children with ASD will continue to increase. In a survey of parental interest in ASD genetic testing from the group, 80 percent of parents indicated that they would want a sibling younger than 2 years tested to identify ASD-risk mutations even if the test could not confirm or rule out the diagnosis.  The team go on to add that for some children with positive genetic test results, treatment plans targeting ASD-associated medical conditions can be offered.  The researchers conclude that if replicated in additional populations, these findings may inform appropriate selection of molecular diagnostic testing for children affected by ASD.

The team surmise that the data indicate that physicians responsible for children with ASD should arrange access to a genetic evaluation using techniques that have the best chance of determining an etiologic diagnosis. For the future the lab state that it is incontrovertible that precise diagnoses pave the way to better medical care, improved surveillance, better functional outcomes, and informed genetic counseling, often with the possibility of prenatal or preimplantation diagnosis.

Source:  The Hospital for Sick Children (SickKids)  


Newer genetic testing methods may provide benefit for children with suspected autism - neuroinnovations

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio,, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

One thought on “Study identifies children with Autism who benefit from genetic testing. Leave a comment

  1. Genetic links to autism and epilepsy are extremely under researched and completely ignored in medicine. Warning: DO NOT use VALPORIC ACID (DEPAKOTE), PHENOBARBITAL or Tylenol—- if the patient has abnormal ANK3 (Ankyrin-G nodes of ranvier) variant. Doctors don’t routinely test for this genetic marker in seizure patients so beware! For instance, if an autistic patient with EPILEPSY develops abnormal behaviors while taking any of these drugs a genetic test should be done to rule out ANK3 de novo missense mutations! Better to use CBD strains of medical cannabis, Vitamin D, Selenium, Lamictal and Racetams like Keppra.

Leave a Reply

Translate »